PSTX

Poseida Therapeutics, Inc. (PSTX) | Rumor.io

Poseida Therapeutics

PSTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PSTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 8

Roche has completed its acquisition of Poseida Therapeutics, Inc. (PSTX) for $1.5 billion, with shareholders receiving $9 per share in cash plus contingent value rights worth up to $4 per share.
The acquisition was completed on January 8, 2025, after a tender offer where Roche accepted nearly 65 million shares of PSTX, representing about 66% of the company's stock.
The deal is expected to strengthen Roche's presence in the biopharmaceutical industry, with Poseida's expertise in complex cell therapies adding to Roche's capabilities.

Generated by AI

Sentiment

Of the messages about PSTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +10.59
Bearish	—	—	—	0% -10.59

Bullish· Nov 27

$PSTX is a potential takeover target, with a possible acquisition price of over $13 per share.
The company's bio peer recently ran 228% in a single day, and another bio stock had a 700% increase last week, suggesting $PSTX is due for a similar surge.
The company's shareholders could receive an additional $4 per share via a CVR (Rights) payment if certain milestones are reached, which would be a significant increase from its current market cap of $275 million.

Bearish· Dec 11

$PSTX has declined by as much as 14.40% in a single session, with trading volume 3406% above average.
The company's stock price has failed to make new highs, forming a double top pattern, and may be experiencing a reversal in trend.
$PSTX has a history of dumping shares after good news, greatly attenuating gains for existing shareholders, and may be experiencing a similar pattern of price suppression.

Generated by AI

Topics

Of the messages about PSTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Nov 27

Roche will acquire Poseida Therapeutics for up to $1.5B, expanding its cell therapy pipeline with CAR-T programs for cancer and autoimmune diseases.
The deal includes $9/share in cash, with closing expected in Q1 2025.
Poseida Therapeutics shares surged 227% on the news of the acquisition.

Generated by AI

Community

Of the messages about PSTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	13.58%
Newcomers	—	—	—	86.42%

Regulars· Nov 26

The deal values Poseida Therapeutics at approximately $1.5 billion, with $9 per share in cash and a non-tradeable contingent value right (CVR) offering up to $4 per share.
Roche's acquisition of Poseida seems to be focused on the company's manufacturing capabilities, technology platforms, and pursuing opportunities outside of hematology malignancies.
The deal includes several of Poseida's cell therapy candidates and related platform technologies, with the acquisition expected to enhance Roche's presence in the cell therapy space.

Newcomers· Nov 29

Newcomers are noticing the price of $PSTX Poseida Therapeutics at $7.35, a decrease of -0.5% with a trade count of 247.
Some newcomers are discussing the large volume of calls ($58.8 K) and puts ($407 K) being traded, indicating significant market interest in $PSTX.
Others are expressing concern about the potential acquisition of $PSTX by Roche, feeling it may not provide fair treatment to shareholders, who see Roche as a company worth $350B.

Generated by AI

Also Discussed

Investors talking about PSTX also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Caribou Biosciences, Inc.CRBU	0%new
3	VIGL - Vigil Neuroscience, Inc.	——
4	INZY - Inozyme Pharma, Inc.	——
5	Century Therapeutics IncIPSC	0%+0
6	Autolus Therapeutics plc ADRAUTL	0%+0
7	C4 Therapeutics IncCCCC	0%-0.01
8	MRSN - Mersana Therapeutics, Inc.	——
9	Beam Therapeutics IncBEAM	0%-0.04
10	Precision BioSciences, Inc.DTIL	0%+0